Navigation Links
Cepheid Schedules 2009 Second Quarter Financial Results Announcement and Webcast
Date:7/9/2009

SUNNYVALE, Calif., July 9 /PRNewswire-FirstCall/ -- Cepheid (Nasdaq: CPHD) today announced that it will report financial results for its second quarter ended June 30, 2009, on Thursday, July 30, 2009, after the close of the market.

The company will host a management presentation at 2 p.m. Pacific Time on Thursday, July 30, 2009, to discuss the results. To access the live webcast, please visit Cepheid's website at www.cepheid.com/investors at least 15 minutes before the scheduled start time to download any necessary audio or plug-in software. A replay of the webcast will be available shortly following the call and will remain available for at least 90 days.

Interested participants and investors may also listen to the live teleconference call by dialing (866) 804-6927 (domestic) or (857) 350-1673 (international), and entering participant code 15214327. A replay will be available for seven days beginning at 4 p.m. Pacific Time. Access numbers for this replay are (888) 286-8010 (domestic) and (617) 801-6888 (international), with participant code 19346894.

About Cepheid

Based in Sunnyvale, Calif., Cepheid (Nasdaq: CPHD) is an on-demand molecular diagnostics company that develops, manufactures, and markets fully-integrated systems and tests for genetic analysis in the clinical, industrial and biothreat markets. The company's systems enable rapid, sophisticated genetic testing for organisms and genetic-based diseases by automating otherwise complex manual laboratory procedures. The company's easy-to-use systems integrate a number of complicated and time-intensive steps, including sample preparation, DNA amplification and detection, which enable the analysis of complex biological samples in its proprietary test cartridges. Through its strong molecular biology capabilities, the company is focusing on those applications where rapid molecular testing is particularly important, such as identifying infectious disease and cancer in the clinical market; food, agricultural, and environmental testing in the industrial market; and identifying bio-terrorism agents in the biothreat market. See http://www.cepheid.com for more information.

    CONTACTS:
    For Media Inquiries:                For Investor Inquiries:
    --------------------                -----------------------
    Jared Tipton                        Jacquie Ross
    Cepheid Corporate Communications    Cepheid Investor Relations
    Tel: (408) 400 8377                 Tel: (408) 400 8329
    jared.tipton@cepheid.com            investor.relations@cepheid.com


'/>"/>
SOURCE Cepheid
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Cepheid Announces Symposium Speakers and Program Highlights for 19th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
2. Cepheid Reports 2009 First Quarter Results
3. Cepheid Schedules Fiscal 2009 First Quarter Financial Results Announcement and Webcast
4. Cepheid Announces New Diagnostic Technology to Aid World Efforts in Halting the Spread of Mycobacterium Tuberculosis (TB)
5. Cepheid Announces Preliminary 2008 Fourth Quarter and Full Year Revenue Results
6. Cepheid to Webcast Upcoming Financial Presentations
7. Cepheid Accelerates Direct Sales Channel in UK With Pending Acquisition of Medical Distributor Stretton Scientific
8. Cepheid Reports Third Quarter Revenue of $44.9 Million
9. Results of United Kingdom MRSA Surveillance Program Using Cepheid GeneXpert(R) System Demonstrate Benefits of Rapid Testing
10. Cepheid Molecular Diagnostic Test for MRSA and S. aureus Categorized Moderate Complexity by FDA
11. Cepheid Schedules Fiscal 2008 Third Quarter Financial Results Announcement and Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... China Biologic Products, Inc. (NASDAQ: CBPO) ("China Biologic" or the ... today announced its financial results for the fourth quarter and ... Financial Highlights Total sales in the ... or increased by 13.6% in USD terms to $77.6 million ... Gross profit increased by 13.3% to $46.8 million ...
(Date:2/23/2017)... ... February 23, 2017 , ... BellBrook ... portfolio to include an array of biochemical analyses critical for Lead Discovery. ... their hit-to-lead and SAR programs, including inhibitor potency and selectivity, mechanism of action, ...
(Date:2/23/2017)... , Feb. 23, 2017  Imanis Life Sciences ... line of oncolytic vaccinia viruses for virotherapy research. ... part of Genelux,s proprietary, vaccinia virus-based technology platform ... to enter into a partnership with Genelux to ... vaccinia viruses for use in research," said Dr. ...
(Date:2/23/2017)... ... 2017 , ... The Greater Gift Initiative, Inc , (GGI) a Winston-Salem, ... . GGI's mission is to advance global health and highlight the greater good of ... of each clinical trial volunteer. The vision of GGI is to serve as a ...
Breaking Biology Technology:
(Date:2/21/2017)... Ore. , Feb. 22, 2017  IBM (NYSE: ... (Avamere Health Services, Infinity Rehab, Signature Hospice, Home Health, ... will apply the power of IBM cognitive computing to ... centers. By analyzing data streaming from sensors in senior ... and environmental conditions, and obtain deeper learnings into the ...
(Date:2/13/2017)... FRANCISCO , Feb. 13, 2017  RSA ... centralized platform that is designed to enhance fraud ... latest release in the RSA Fraud & Risk ... enable organizations to leverage additional insights from internal ... tools to better protect their customers from targeted ...
(Date:2/8/2017)... YORK , Feb. 8, 2017 About ... individual,s voice to match it against a stored ... such as pitch, cadence, and tone are compared ... require minimal hardware installation, as most PCs already ... for different transactions. Voice recognition biometrics are most ...
Breaking Biology News(10 mins):